Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6H46

Human KRAS in complex with darpin K13

6H46 の概要
エントリーDOI10.2210/pdb6h46/pdb
分子名称GTPase KRas, darpin K13, GUANOSINE-5'-DIPHOSPHATE, ... (5 entities in total)
機能のキーワードgtp-ase, darpin, kras signalling, signaling protein
由来する生物種Homo sapiens (Human)
詳細
タンパク質・核酸の鎖数2
化学式量合計36676.03
構造登録者
主引用文献Bery, N.,Legg, S.,Debreczeni, J.,Breed, J.,Embrey, K.,Stubbs, C.,Kolasinska-Zwierz, P.,Barrett, N.,Marwood, R.,Watson, J.,Tart, J.,Overman, R.,Miller, A.,Phillips, C.,Minter, R.,Rabbitts, T.H.
KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe.
Nat Commun, 10:2607-2607, 2019
Cited by
PubMed Abstract: Inhibiting the RAS oncogenic protein has largely been through targeting the switch regions that interact with signalling effector proteins. Here, we report designed ankyrin repeat proteins (DARPins) macromolecules that specifically inhibit the KRAS isoform by binding to an allosteric site encompassing the region around KRAS-specific residue histidine 95 at the helix α3/loop 7/helix α4 interface. We show that these DARPins specifically inhibit KRAS/effector interactions and the dependent downstream signalling pathways in cancer cells. Binding by the DARPins at that region influences KRAS/effector interactions in different ways, including KRAS nucleotide exchange and inhibiting KRAS dimerization at the plasma membrane. These results highlight the importance of targeting the α3/loop 7/α4 interface, a previously untargeted site in RAS, for specifically inhibiting KRAS function.
PubMed: 31197133
DOI: 10.1038/s41467-019-10419-2
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.22 Å)
構造検証レポート
Validation report summary of 6h46
検証レポート(詳細版)ダウンロードをダウンロード

252091

件を2026-04-15に公開中

PDB statisticsPDBj update infoContact PDBjnumon